UniProtKB/Swiss-Prot Q9UBP0 : Variant p.Ser445Asn
Spastin
Gene: SPAST
Feedback ?
Variant information
Variant position:
445
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
US
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Asparagine (N) at position 445 (S445N, p.Ser445Asn).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to medium size and polar (N)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In SPG4; uncertain significance.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
445
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
616
The length of the canonical sequence.
Location on the sequence:
ALFAVARELQPSIIFIDEVD
S LLCERREGEHDASRRLKTEF
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ALFAVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Mouse ALFAVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Rat ALFAVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Pig ALFAVARELQPSIIFIDEVDS LLRERREGEHDASRRLKTEF
Bovine ALFAVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Chicken ALFAVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Xenopus laevis ALFSVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Xenopus tropicalis ALFSVARELQPSIIFIDEVDS LLCERREGEHDASRRLKTEF
Zebrafish ALFAVARELQPSIIFIDEIDS LLCERREGEHDASRRLKTEF
Caenorhabditis elegans GLFQIARNAQPSIIFIDEIDS ILCERSEKDAEVSRRMKTEF
Drosophila ALFAVARHMQPSIIFIDEVDS LLSERSSSEHEASRRLKTEF
Slime mold ALFAVATHFQPSIIFIDEIDS LLTERSSNESEASRRLKTEI
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 616
Spastin
Topological domain
78 – 616
Cytoplasmic
Region
228 – 616
Sufficient for microtubule severing
Mutagenesis
442 – 442
E -> Q. Abrogates ATP hydrolysis, abolishes microtubule severing, stabilizes the homohexameric form, and promotes microtubule binding and redistribution from the endosome to microtubules.
Mutagenesis
448 – 448
C -> AG. Abolishes ATPase activity.
Mutagenesis
448 – 448
C -> S. Does not affect ATPase activity.
Mutagenesis
451 – 451
R -> G. Abrogates binding to the tail of alpha-tubulin and beta-3-tubulin, impairs ATPase activity and abolishes microtubule severing.
Mutagenesis
457 – 457
A -> E. Abrogates binding to the tail of alpha-tubulin and beta-3-tubulin and abolishes microtubule severing.
Helix
443 – 446
Literature citations
Hereditary spastic paraplegia due to SPAST mutations in 151 Dutch patients: new clinical aspects and 27 novel mutations.
de Bot S.T.; van den Elzen R.T.; Mensenkamp A.R.; Schelhaas H.J.; Willemsen M.A.; Knoers N.V.; Kremer H.P.; van de Warrenburg B.P.; Scheffer H.;
J. Neurol. Neurosurg. Psych. 81:1073-1078(2010)
Cited for: VARIANTS SPG4 ILE-162; LYS-356; SER-365; ARG-382; ILE-407; PHE-422; ASN-445; SER-460; LEU-482; GLU-512 DEL; VAL-534 AND PRO-562; VARIANT LEU-44;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.